HIGHLIGHTS
- who: Nouf Al-Subhi from the Translational Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham , PB, UK have published the paper: Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy, in the Journal: (JOURNAL)
- what: The authors provide evidence that ATR and pChk1 expression in of PTEN-deficient breast cancer adversely impact on survival. Supporting these observations, the study demonstrated that cytoplasmic/nuclear PTEN loss resulted in significantly increasing tumour size, mitotic index and NPI.
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.